GMAB

Genmab A/S ADS
D

GMAB

Arincen61/100B

Genmab A income statement 2002–2026

4.30B USD over the last twelve months, and 3.72B USD in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Revenue
4.30B3.72B21.53B16.47B14.51B8.42B10.11B5.37B3.03B2.37B1.82B
Revenue growth
-49.42%-82.70%+30.67%+13.57%+72.33%-16.75%+88.43%+77.38%+27.89%+30.25%+60.29%
Cost of revenue
318.00M309.24M985.00M226.00M0.000.000.000.000.000.000.00
Gross profit
3.98B3.41B20.54B16.25B14.51B8.42B10.11B5.37B3.03B2.37B1.82B
Gross margin
92.60%91.69%95.42%98.63%100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Research and development
1.88B1.56B9.75B7.63B5.56B4.18B3.14B2.39B1.43B874.28M660.88M
Selling, general and administrative
774.99M602.47M3.79B3.30B2.68B1.28B661.00M342.00M213.70M146.99M102.41M
Operating expenses
2.66B2.16B13.84B10.93B8.24B5.46B3.80B2.73B1.64B1.02B763.29M
1.32B1.25B6.70B5.32B6.27B2.95B6.31B2.64B1.38B1.34B1.05B
Operating income growth
-56.23%-81.34%+25.97%-15.09%+112.22%-53.22%+139.31%+91.12%+2.69%+27.67%+44.15%
Operating margin
30.63%33.60%31.14%32.30%43.21%35.08%62.44%49.16%45.63%56.83%57.97%
Interest income
122.91M138.11M995.00M939.00M324.00M197.00M184.00M120.00M62.92M41.00M32.58M
Interest expense
377.28M61.05M120.00M27.00M21.00M13.00M10.00M7.00M417.00K2.00M213.00K
Other non-operating income
-537.99M-46.04M2.46B316.00M678.00M965.00M-409.00M221.00M231.69M-280.45M77.38M
Pretax income
778.11M1.20B9.16B5.64B6.95B3.92B5.90B2.86B1.61B1.06B1.13B
Income tax
49.01M241.19M1.32B1.29B1.49B961.00M1.15B693.00M139.83M-39.83M-56.86M
Effective tax rate
6.30%20.02%14.40%22.80%21.50%24.53%19.41%24.24%8.67%-3.74%-5.03%
729.10M963.76M7.84B4.35B5.45B2.96B4.76B2.17B1.47B1.10B1.19B
Net income growth
-84.19%-87.71%+80.24%-20.18%+84.38%-37.85%+119.67%+47.13%+33.40%-7.04%+55.48%
Net margin
16.97%25.89%36.44%26.42%37.59%35.13%47.06%40.37%48.66%46.65%65.36%
Basic shares
614.07M621.51M646.33M659.15M653.87M653.96M651.79M629.63M612.68M608.34M598.76M
Diluted shares
637.24M626.92M646.33M659.15M660.10M660.46M658.86M636.37M620.45M620.94M617.66M
Change in diluted shares
+1.09%-3.00%-1.94%-0.14%-0.05%+0.24%+3.53%+2.57%-0.08%+0.53%+1.63%
EPS (basic)
1.191.5512.146.608.344.527.303.442.401.811.98
EPS (diluted)
1.171.5412.146.608.264.487.223.402.371.781.92
EPS growth
-83.82%-87.31%+83.94%-20.10%+84.38%-37.95%+112.35%+43.46%+33.15%-7.29%+52.38%
EBITDA
1.21B1.34B9.70B6.00B7.35B4.18B6.17B3.01B1.70B1.44B1.17B
EBITDA margin
28.13%35.91%45.05%36.42%50.64%49.66%61.05%56.00%56.20%60.72%64.50%
EBIT
1.16B1.27B9.28B5.71B6.97B3.93B5.91B2.87B1.61B1.37B1.13B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Figures underlined with dots are from the company's SEC filings, where our data provider's differ.

Common questions about Genmab A's income statement

Source: Financial Modeling Prep